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bstract
Cardiovascular diseases (CVD) such as myocardial infarction and stroke are a major cause of morbidity and mortality worldwide. Impairment
f the normal vasorelaxant functions of the vascular endothelium, termed endothelial dysfunction; appear to underlie the pathogenesis of CVD.
ndothelial dysfunction is often secondary to abnormal increases in oxidative stress, inflammation and overactivity of the renin–angiotensin system
RAS), which makes these pathways attractive targets for therapeutic interventions. Given the side-effects associated with synthetic pharmaceutical
gents, there is growing interest in using natural products such as bioactive peptides for treating chronic diseases like CVD. In this review, we
iscuss the potential for bioactive peptides with antioxidant, anti-inflammatory and RAS modulating properties for treating endothelial dysfunction
nd preventing CVD.
 2015 Beijing Academy of Food Sciences. Production and hosting by Elsevier B.V. All rights reserved.
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.  Introduction
Cardiovascular diseases such as myocardial infarction and
troke are leading causes of morbidity and mortality [1]. Taken
ogether, these two conditions caused 249.7 deaths/100,000 per-
ons in 2013 and contributed to 28.2% of all deaths worldwide
2]. The key underlying pathology in cardiovascular disorders
s atherosclerosis, the inflammatory thickening of the blood
essel wall [3]. Additional vascular factors predisposing to
therosclerosis include hypertension [4], the persistent elevation
f blood pressure above 140/90 mmHg [5]. Both atheroscle-
osis and hypertension originate from impaired functioning of
he endothelium, the monolayer of cells that line the lumen of
lood vessels [6,7]. Thus, the endothelium is a key factor for
aintaining vascular health and prevention of cardiovascular
iseases.
While a number of pharmacological agents are widely
sed for prevention, treatment and long-term management of∗ Corresponding author at: 4-10 Ag/For Centre, Department of Agricultural,
ood & Nutritional Science, University of Alberta, Edmonton, AB T6G 2P5,
anada. Tel.: +1 780 492 6885; fax: +1 780 492 4265.
E-mail address: jianping.wu@ualberta.ca (J. Wu).
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ascular diseases, these drugs are not without the risk of sig-
ificant side-effects [8,9]. Not surprisingly, there has been an
ncreased interest in developing alternative therapies from nat-
ral sources, which are commonly perceived to be safer than
ynthetic drugs. Naturally occurring proteins and their con-
tituent peptides are an attractive source for novel natural
ompounds with various biological activities [10]. Bioactive
eptides are defined as relatively short peptides (typically con-
aining 2–20 amino acids) derived from their parent proteins
by enzymes, heat, chemical treatments or microbial fermenta-
ion) that demonstrate additional biological activities over and
bove their expected nutritional value [11,12]. Recent years have
een much interest in using bioactive peptides (and peptide-rich
rotein hydrolysates) from food sources as safe and natu-
al alternatives for promoting and enhancing health [13–15].
his review will provide an overview of the potential roles of
ioactive peptides in maintaining endothelial functions and/or
reventing endothelial dysfunction through modulation of dif-
erent physiological pathways..  Endothelial  functions  and  dysfunction
Over the past few decades, the roles of the endothelium
n vascular physiology have become better understood. While
lsevier B.V. All rights reserved.
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Fig. 1. Endothelial functions under normal (physiological) and abnormal (patho-
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riginally it was believed to be simply an inert layer of cells
eparating blood from the structural tissues, it is now well
nown for its critical roles in regulating vascular tone. Research
rom the last 20 years has defined many crucial roles for the
ndothelium in the regulation of vascular tone, modulation of
nflammation, promotion or inhibition of vascular growth and
f platelet aggregation and coagulation, and in the development
f atherosclerosis [16].
The vascular endothelium is considered to be the largest
ndocrine organ in the body. Endothelial cells secrete vari-
us vasoactive agents, such as the vasodilatory nitric oxide
NO), prostacyclin, and endothelium-derived hyperpolarizing
actor (EDHF), as well as the vasoconstrictory endothelin I,
ngiotensin II (Ang II) and thromboxane [17,18]. Endothelial
ysfunction is a broad term that implies diminished produc-
ion or availability of NO and/or an imbalance in the relative
ontribution of endothelium-derived relaxing and contracting
actors [19]. Endothelial dysfunction has been shown in the
lderly, in patients with hypertension, diabetes and hypercho-
esterolemia as well as in those subjected to air pollution
r smoking [16,20,21]. Such dysfunction is involved in the
athophysiology of metabolic syndrome and cardiovascular dis-
ases such as atherosclerosis, hypertension and heart failure
22,23]. Reduced bioavailability of endothelium-derived NO
s the key for endothelial dysfunction. NO relaxes blood ves-
els (vasodilation), prevents thrombus formation, suppresses
mooth muscle proliferation, and inhibits the leukocyte attach-
ent to the activated endothelium [16,24]. Loss of endothelial
O bioavailability, a key manifestation of endothelial dysfunc-
ion, is increasingly accepted as a common trait of essentially
ll cardiovascular risk factors, showing profound prognostic
mplications in prediction of adverse cardiovascular events and
ong-term outcomes [25]. A number of pathological mechanisms
ppear to mediate endothelial dysfunction in general, including
xidative stress, dysregulated inflammation and overactivity of
he renin–angiotensin system (RAS) all of which are potential
argets for modulation by bioactive peptides. The key endothe-
ial functions and their altered dysfunctional counterparts are
ummarized in Fig. 1.
.  Bioactive  peptides  on  NO  bioavailability  and
ndothelial function
.1.  Oxidative  stress,  NO  and  endothelial  dysfunction
Oxidative stress, i.e.  the excessive and/or dysregulated gener-
tion of reactive oxygen species (ROS) such as superoxide and
ydrogen peroxide, is a major contributor to disease patholo-
ies. In the vascular endothelium, an excess of superoxide leads
o its reaction with NO to generate peroxynitrite (ONOO−),
 highly reactive and toxic molecule that causes nitration
t the tyrosine residues of various proteins. Not only does
eroxynitrite formation reduce NO bioavailability (and hence
ontributes to endothelial dysfunction), tyrosine nitration can
lso adversely affect physiological functions of many cellular
roteins, predisposing the endothelial cells toward inflammation
nd cell death [26,27]. In addition, high ROS levels also induce
a
b
l
oogical) conditions.
ncoupling of the NO generating enzyme endothelial nitric
xide synthase (eNOS), further jeopardizing the vascular
unctions [28]. Given the critical roles played by NO and its alter-
tions observed under oxidative stress, regulation of ROS levels
s a key area for enhancing or maintaining normal endothelial
unctions.
.2.  Antioxidant  bioactive  peptides
Recently, antioxidant peptides derived from hydrolysis of
ood proteins such as those from milk, egg, meat, wheat and soy
ave been reported [29–34]. Most peptides were characterized
ased on either radical-scavenging activity or metal-chelating
ctivity; however, all these chemical assays are performed under
ell-free in  vitro  conditions, making it impossible to extrapolate
he results to in  vivo  situations [35]. Hence it is of great impor-
ance to evaluate the bioactivity of antioxidant peptides under
hysiological conditions to establish their protective roles in dis-
ases. To date, only a limited number of studies have evaluated
he role of antioxidant peptides under physiologically relevant
onditions.
For example, glutathione (GSSH), was found to reverse the
mpaired relaxation of aortas from spontaneously hypertensive
ats (SHR) to acetylcholine; an effect which was of compara-
le magnitude to other antioxidants such as aminotriazole and
scorbic acid, when given intraperitoneally at the same dose
36]. The effect of GSSH was also observed in human subjects,
articular with vascular dysfunction [37,38]. Data from our labo-
atory have shown antioxidant properties of egg derived peptides
le-Arg-Trp and Ile-Gln-Trp which may contribute toward their
nti-hypertensive and vasorelaxant effects observed in animal
tudies as described later [39,40]. Milk derived peptides with
ntioxidant activity can improve vascular function and reduce
lood pressure although additional mechanisms such as modu-
ation of vasoactive factors are likely to contribute toward the
bserved beneficial effects [29].
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.3.  NO  generation  by  bioactive  peptides
Apart from improving NO bioavailability through antioxi-
ant effects, certain peptides can also directly induce endothelial
O formation and hence, contribute to improved endothelial
unctioning. For example, the whey derived peptide NOP-
7, a direct stimulator of endothelial NO, has been shown to
mprove endothelium-dependent vasorelaxation and increase
lasma nitrate/nitrite levels (a measure of physiological NO for-
ation in  vivo) in a randomized clinical trial in healthy human
ubjects [41]. Similarly, flaxseed protein hydrolysate, contain-
ng arginine-rich peptides, can reduce blood pressure in SHRs,
resumably through the enhanced NO generating effects of
rginine [42]. The relaxing effect of peptide (Arg-Ala-Asp-His-
ro-Phe), an ovokinin (2–7), derived from chymotryptic digest
f egg white protein ovalbumin, showed endothelium-dependent
asorelaxation in an isolated SHR mesenteric artery via  de
ovo NO generation [43]. Carnosine is a dietary endogenous
ipeptide (beta-Ala-L-His) present mainly in skeletal muscle
issue [44]. Apart from directly stimulating NO formation in
ultured endothelial cells [45], carnosine also showed dose-
ependent relaxation effects on isolated aortic rings [46]; this
elaxation appeared to be endothelium independent and is likely
ue to the generation of cGMP although additional effects of
ndothelium-generated second messengers could not be ruled
ut. Interestingly, vasoconstriction was the response to carnosine
n rabbit saphenous vein rings, suggesting its opposite vasoactive
oles in different vascular beds [47].
.4.  Opioid  peptides  and  vasorelaxation
Bioactive peptides with opioid activity are another class of
ascular regulators. Two opioid peptides, -lactorphin (Tyr-Gly-
eu-Phe) and -lactorphin (Tyr-Leu-Leu-Phe), derived from
ilk protein -lactalbumin and -lactoglobulin, respectively,
ind to opioid receptors and show weak opioid activity in  vivo
48]. Indeed, -lactorphin reduces the blood pressure in SHRs
howing direct vasoactive effects [49]. Both peptides demon-
trated endothelium-dependent vasorelaxation ex  vivo, involving
O since the relaxation was abolished by the NO synthase
NOS) inhibitor NG-nitro-l-arginine methyl ester (l-NAME)
ather than endothelium-derived hyperpolarizing factor (EDHF)
r vasorelaxant prostanoids [50]. Surprisingly, Casoxin D (Tyr-
al-Pro-Phe-Pro-Pro-Phe), an anti-opioid peptide identified
rom pepsin-chymotrypsin digest of human casein, also pro-
oted vascular relaxation mediated by bradykinin B1 receptors
hich could be antagonized by a cyclooxygenase inhibitor [51].
n contrast, casomokinin L (Tyr-Pro-Phe-Pro-Pro-Leu) relaxed
anine mesenteric artery rings in endothelium-dependent and
O-mediated manner, suggesting further complexity in the roles
f opioid receptors and vasorelaxation [52].
.  Bioactive  peptides  on  inﬂammation.1.  Inﬂammation  and  endothelial  dysfunction
Inflammation plays an essential role for the vascular endothe-
ium. In response to sub-lethal injury, endothelial cells respond
l
f
p
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ith increased permeability and upregulated leukocyte adhe-
ion molecules which enable recruitment of leukocytes on the
ndothelium followed by their migration across the vascular
arrier [53]. While inflammation is essential for the body’s
efenses against microbes and other injurious stimuli, exces-
ive and persistent inflammatory changes can lead to vascular
athologies like atherosclerosis and its complications. Inflam-
ation by itself can activate the endothelial cells; the associated
ncrease in permeability could alter its vasodilatory properties,
hile the concomitant increase in ROS formation would further
ttenuate the vascular relaxation [54]. In addition, inflammatory
ecruitment of leukocytes to the sub-endothelial space is a major
ontributor to atherosclerotic plaque formation and subsequent
ardiovascular disease [55].
.2.  Anti-inﬂammatory  bioactive  peptides
Bioactive peptides with known anti-inflammatory effects are
otential candidates for improving endothelial dysfunction. In
ontrast to antioxidant peptides, nearly all anti-inflammatory
nes have been validated in physiologically relevant systems
ike cultured cells and animal models, which improve their
hances of in  vivo  biological actions. In spite of this, few of
he anti-inflammatory peptides identified to date have been
pecifically tested for improvements in vascular/endothelial
unctions.
Research in our laboratory had identified an egg protein
votransferrin derived tripeptide, Ile-Arg-Trp, as a potential
CE (angiotensin converting enzyme) inhibitory molecule [40].
urther testing of this peptide determined its additional anti-
nflammatory and antioxidant effects on cultured endothelial
ells [56]. These functions were validated in an in  vivo  study
nvolving SHRs where this peptide reduced blood pressure,
mproved endothelium-dependent vasorelaxation (as shown
n ex  vivo  study) and attenuated markers of inflammation,
howing correlation between cell-based and whole animal stud-
es [57]. Another ovotransferrin derived peptide, Ile-Gln-Trp
lso showed similar anti-inflammatory effects on endothe-
ial cells and comparable vasculo-protective roles in SHRs
39,58]. It is likely that a combination of factors such as anti-
nflammatory properties, ACE inhibition and improved NO
ioavailability all contributed to the final outcomes in both
ases.
Peptide-rich milk protein hydrolysates have shown anti-
nflammatory effects in cultured endothelial cells and appear
o inhibit leukocyte-endothelial interactions [59], which may
xplain some of their beneficial vascular/endothelial roles in
ddition to better known ACE inhibitory effects. A gastric
nzyme hydrolysate of Spirulina (a type of sea weed) yielded
 peptides (Leu-Asp-Ala-Val-Asn-Arg and Met-Met-Leu-Asp-
he) with similar anti-inflammatory effects on endothelial cells
60], while other bioactive peptides such as Ser-Ser-Ser, Glu-
lu-Glu and Val-Pro-Leu have all been shown to attenuateeukocyte-endothelial interactions [61]. Given the crucial role
or inflammatory leukocyte recruitment in atherosclerosis, such
eptides may help maintain normal endothelial functions in an
nflamed environment.
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Table 1
Endothelial functions of bioactive peptides.
Endothelial functions Peptide Source protein Experimental system References
Antioxidant Glutathione SHR/Male WKY rat,
human subjects
[36]
Antioxidant, ACE-inhibitor, anti-inflammatory Ile-Arg-Trp Ovotransferrin Endothelial cells, SHR [56,57]
Antioxidant, ACE-inhibitor, anti-inflammatory Ile-Gln-Trp Ovotransferrin Endothelial cells, SHR [39,58]
NO generation NOP-47 Whey protein Human subjects [41]
NO generation/opioid agonist A-lactorphin
(Tyr-Gly-Leu-Phe)
A-lactabumin Isolated mesenteric
arterial ring of SHR
[50]
NO generation/opioid agonist A-lactorphin
(Tyr-Leu-Leu-Phe)
A-lactoglobulin Isolated mesenteric
arterial ring of SHR
[50]
NO generation Arg-Ala-Asp-His-Pro-Phe Ovalbumin Isolated mesenteric
arterial ring of SHR
[43]
NO generation Arginine-rich cationic
peptides
Flaxseed protein SHR [42]
NO generation Carnosine Skeletal muscle
protein
Endothelial cells (f-2) [45]
NO generation Casomokinin L
(Tyr-Pro-Phe-Pro-Pro-Leu)
Human casein Canine isolated
mesenteric arterial ring
[52]
Anti-inflammatory Leu-Asp-Ala-Val-Asn-Arg Spirulina protein Endothelial cells [60]
Anti-inflammatory Met-Met-Leu-Asp-Phe Spirulina protein Endothelial cells [60]
ACE inhibition Val-Tyr Sardine SHR, mice [70,71]
ACE inhibition Val-Pro-Pro Casein Endothelial cells, SHR,
human subjects
[74,76]
ACE inhibition, ACE2 upregulation Ile-Pro-Pro Casein Endothelial cells, SHR,
human subjects
[74–76,80]
ACE inhibition Peptide-rich hydrolysate Thai rice bran protein 2K1-C rats [77]
AT1R blocker Leu-Ile-Trp-Lys-Leu Lactoferrin Isolated rabbit carotid
arteries, receptor binding
assays
[81]
AT1R blocker Arg-Pro-Tyr-Leu Lactoferrin, egg
protein
Isolated rabbit carotid
arteries, receptor binding
assays
[81]
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.  Bioactive  peptides  as  RAS  modulators
.1.  Renin–angiotensin  system  (RAS)  and  endothelial
ysfunction
RAS is a significant regulator of vascular functions, with
ng II being one of the most potent vasoconstrictors known
62]. While much of these effects occur at the VSMC
evel, excessive RAS actions can also be deleterious to the
ndothelium. For example, Ang II can lead to inflammatory
hanges, matrix metalloproteinase-2 (MMP-2) release and ROS
eneration in endothelium, with their adverse consequences
n endothelial vasorelaxant properties [63–65]. In addition,
ndothelial cells are a source of ACE, the critical enzyme
nvolved in generation of Ang II from its inactive precur-
or Ang I. On the other hand, ACE2 (angiotensin converting
nzyme 2), the negative regulator of RAS, is associated with
nti-inflammatory effects and improved vascular functions, sug-
esting a more complex role for RAS as an endothelial regulator
66,67]..2.  RAS  regulation  by  bioactive  peptides
Initial studies of bioactive peptides as ACE inhibitors were
ostly done by biochemical assays in cell-free in  vitro  systems.
s
t
a
[Egg white protein SHR [82]
owever, many such studies have now been followed up with
ellular and animal studies validating the original observations.
or example, previous work on egg white protein ovotransferrin
ydrolysates in our laboratory identified a number of tripeptides
ith ACE antagonist properties, which were later confirmed to
ave significant effects on blood pressure reduction and atten-
ation of plasma Ang II levels in SHRs [57,58,68]. Another
CE inhibitor peptide Val-Tyr, derived from sardines, also
educed blood pressure in SHRs and transgenic hypertensive
ice [69,70]. This peptide specifically inhibited Ang I-evoked
ontraction, but not those by Ang II since pre-incubation with
his peptides did not affect the contraction evoked by directly
dding Ang II to the bath; the inhibition of Ang I contrac-
ion was probably due to the inhibition of ACE within the
ascular wall [71]. Two tripeptides derived from the milk pro-
ein casein, namely Ile-Pro-Pro and Val-Pro-Pro, have ACE
nhibitory functions and have demonstrated improvements in
oth ex vivo  vasorelaxation as well as in  vivo  blood pressure
ontrol [72–74]. It appears that additional vasculo-protective
echanisms such as enhancement of endothelial NO generation
ay contribute to these observed effects [75]. A study in humanubjects also showed marked improvements in the augmenta-
ion index, a marker of endothelial dysfunction, upon long-term
dministration of a fermented milk drink rich in these peptides
76].
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Recently, the enzymatic hydrolysate of rice bran protein,
ontaining a number of different bioactive peptides, has been
hown to reduce blood pressure and improve endothelium-
ependent vasorelaxation in 2K-1C rats, likely through ACE
nhibitory action of this preparation [77]. In a similar vein,
asein hydrolysates with in  vitro  ACE inhibitory properties also
emonstrated attenuation of ex  vivo  vasoconstriction as well
s reduction of blood pressure in  vivo, further validating the
otential of ACE inhibitor peptides and peptide-rich protein
ydrolysates to improve vascular functions [78].
Apart from ACE inhibition, other mechanisms targeting dif-
erent components of RAS are under investigation. A recent
tudy from our laboratory has shown the ability of egg derived
eptide Ile-Arg-Trp to upregulate ACE2 expression in the vas-
ulature of SHRs [79]; together with the well-characterized
CE-inhibitory and anti-inflammatory actions, this could be
nother pathway to exert its beneficial effects. Similar effects
f Ile-Pro-Pro on ACE2 were also determined by Ehlers et  al.
80]. As the vasoconstrictory effects of Ang II are largely medi-
ted through its receptor AT1R (Ang II receptor type 1), it is
lso a target for modulation by bioactive peptides. For example,
everal peptides such as Arg-Pro-Tyr-Leu (from milk or egg)
nd the milk-derived Leu-Ile-Trp-Lys-Leu can act by inhibi-
ing Ang II binding to AT1R, which shows in  vivo  reduction of
lood pressure in SHRs [81]. A multi-functional egg peptide,
rg-Val-Pro-Ser-Leu, exerts its beneficial vasorelaxant effects
hrough reductions in levels of ACE, renin, Ang II and kidney
T1R in SHRs, further demonstrating the potential of bioactive
eptides in regulating RAS for vascular functions [82].
The bioactive peptides with endothelial functionalities are
ummarized in Table 1.
.  Conclusions
In conclusion, bioactive peptides are an attractive option for
reating and managing endothelial dysfunction and its com-
lications, based on potential modulation of oxidative stress,
nflammation and RAS overactivity. However, several chal-
enges remain to be overcome before widespread acceptance
nd commercial usage of such peptides can become the norm.
pecific issues include the lack of knowledge regarding peptide
eceptors and pharmacokinetics, the incomplete understanding
f potential allergenic/immunogenic peptide sequences as well
s limited information regarding dosage regimens, safety data
nd side effects. Future studies should involve further basic
iomedical research to elucidate the molecular mechanisms of
ction that underlie the promising results observed with these
eptides on improving endothelial/vascular health. Clinical tri-
ls, especially those performed with strict randomization, would
lso help to move more bioactive peptides from the bench to the
ed side, with expected benefits for both the people at risk of
VD and the health care system as a whole.
cknowledgementsThis study was supported by Alberta Livestock and Meat
gency (ALMA) and Natural Sciences and Engineering
esearch Council of Canada (NSERC).
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